Boston Scientific Corporation ORISE Gel Syringe Submucosal Lifting Agent Kits: indicated for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers or other gastrointestinal mucosal lesions, prior to excision with a snare or other suitable endoscopic device UPN: (1)Twin Pack Box 1 M00519210; (2)Twin Pack Box 10 M00519211; (3)Single Pack Box 10 M00519231 Recall

Check Your Product

According to the U.S. Food and Drug Administration (FDA)

Reason for Recall

As stated by FDA

***Update12/13/22***:Product removal due to higher incidence of adverse events of foreign body reactions*** Potential outcomes associated with foreign body reaction to remnant ORlSE Gel post procedure. Foreign body reaction which presented as mass formations from remnant ORlSE Gel post-procedure, prompting surgical intervention

Recommended Action

Per FDA guidance

***UPDATE 12/13/22** Boston Scientific issued Urgent Medical Device Product Removal Immediate Action Required Orise" Gel Submucosal Lifting Agent via Federal Express Priority Overnight mail on December 14, 2022, (as a Follow-Up To The Previous Product Advisory Dated October 10, 2022). Letter states reason for recall (Product Removal), health risk and action to take: Use and distribution of any remaining unused ORISE Gel Submucosal Lifting Agent products affected by this removal should cease immediately. For patients already treated with ORISE Gel, should the user identify submucosal distortions or mass formations in follow-up endoscopy, endoscopic ultrasound, imaging, or surgery, Boston Scientific recommends taking into account prior ORISE Gel use. Review pathology reports from the prior procedure to help determine the most appropriate course of action. Depending on the pathology present during the initial use of ORISE Gel, and whether it included conditions such as adenoma, high-grade dysplasia, or malignancy, a user may need to do nothing, repeat surveillance, repeat a biopsy, perform further mucosal resection, or plan surgical intervention to rule out any residual lesion. For each patient treated with ORISE Gel, Boston Scientific recommends appending their medical record with a copy of this letter to maintain awareness of this topic. If you identify any product from the affected lots within your inventory, please segregate the product immediately and return it to Boston Scientific in accordance with the enclosed Removal Instructions. If you are a distributor, please note that the depth of this removal is to the end user level and this notification should be forwarded to your customers. If you are a facility that has sent products to another hospital or facility within your network, please ensure that this notification is forwarded to them. Your local Sales Representative can answer any questions that you may have regarding this notification. _________________